Evidence map›Paper›PMID 26420956›Full record

ReviewWorld journal of gastroenterology2015

Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation.

Masatoshi Ishigami, Yasuhiro Ogura, Yoshiki Hirooka, Hidemi Goto

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Masatoshi IshigamiMasatoshi Ishigami, Yoshiki Hirooka, Hidemi Goto, Department of Gastroenterology and Hepatology, Nagoya University School of Medicine, Nagoya 466-8550, Japan.
Yasuhiro OguraMasatoshi Ishigami, Yoshiki Hirooka, Hidemi Goto, Department of Gastroenterology and Hepatology, Nagoya University School of Medicine, Nagoya 466-8550, Japan.
Yoshiki HirookaMasatoshi Ishigami, Yoshiki Hirooka, Hidemi Goto, Department of Gastroenterology and Hepatology, Nagoya University School of Medicine, Nagoya 466-8550, Japan.
Hidemi GotoMasatoshi Ishigami, Yoshiki Hirooka, Hidemi Goto, Department of Gastroenterology and Hepatology, Nagoya University School of Medicine, Nagoya 466-8550, Japan.
Nagoya University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A few decades ago, liver transplantation in patients with chronic hepatitis B virus (HBV) infection was considered a relative contraindication because of the high rate of graft infections and poor prognosis. Since then, remarkable progress was introduced by using nucleos(t)ide analogues and/or hepatitis B immunoglobulin (HBIg) and liver transplantation for HBV-related disease is now becoming one of the good indication. However, high cost burden is the main problem for this combination prophylaxis for a long time use, and this issue should be emerged to be resolved. In this review, we show the progress of post anti-HBV strategies showing the history from introduction of HBIg and nucleos(t)ide analogues to recent new strategies with hepatitis B vaccine or saving or stopping protocols of HBIg, and clarify and discuss how to do for further improvement of prevention strategies with better quality.

Indexed as

Virus ActivationAntiviral AgentsEnd Stage Liver DiseaseGenotypeHepatitis B, ChronicHepatitis B virusHumansImmunoglobulinsLiver TransplantationMutationPhenotypeRecurrenceRisk FactorsTreatment OutcomeAntiviral Agentshepatitis B hyperimmune globulinImmunoglobulinsEscape mutantHepatitis B immunoglobulinHepatitis B vaccineHepatitis B virusLiver transplantationNucleos(t)ide analogueProphylaxis

Identifiers

PMID26420956
PMCPMC4579876
OpenAlexW2418046349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.